[CLSTR]
< Back to situation

[REVISION HISTORY]

Brazil pharmaceutical supply and production strategy

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-03 19:44 UTC → 2026-08-19 23:58 UTC · added removed

Brazil pharmaceutical supply challenges and production strategy

In late July 2026, Brazil reported severe drug shortages at high‑cost medication centers, with patients experiencing long waits and missing essential treatments for conditions such as cancer and epilepsy. The At the Cemac Juarez Barbosa in Goiânia, patients reported insufficient staffing and a lack of medication, forcing some to risk their employment. These shortages were linked to global supply‑chain strains affecting active pharmaceutical ingredients and to delays from the Ministry of Health and vendors. By early August, attention the focus shifted to the structural causes causes. While approximately 70% of those shortages. Industry officials noted that while most medicines consumed in Brazil are produced locally, the sector depends heavily on imported active ingredients from China and India, creating production bottlenecks. Additional pressures include trade‑defence weaknesses, facing hurdles such as high logistics costs, costs and regulatory hurdles. A concurrent trade‑defence weaknesses. Concurrently, a study highlighted widespread revealed that roughly 90% of Brazilians engage in self‑medication, raising safety concerns about with toxicologists warning that improper use of over‑the‑counter drug misuse drugs increases risks of kidney injury and its gastrointestinal bleeding. In response to these vulnerabilities and the significant trade deficit in health impacts. Together, products, the snapshots illustrate Brazilian government announced a developing picture strategic goal in mid-August to increase domestic production of Brazil’s pharmaceutical system grappling with both immediate supply gaps medicines and longer‑term manufacturing active pharmaceutical ingredients to 70% of the Unified Health System (SUS) needs by 2033. To achieve this, Vice President Geraldo Alckmin highlighted tax reforms providing exemptions for certain inputs and safety challenges. the authorization of the BNDES to support companies accessing international markets under the ‘Plano Brasil Soberano’.

Versions

  1. 2026-08-19 23:58 UTC Brazil pharmaceutical supply and production strategy
  2. 2026-08-03 19:44 UTC Brazil pharmaceutical supply challenges

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.